Agilis Biotherapeutics Presents at BIO Investor Forum

Cambridge, MA, October 22, 2015 -- Agilis Biotherapeutics, LLC (Agilis), a biotechnology company advancing innovative DNA therapeutics for rare genetic diseases that affect the central nervous system (CNS), announced today that Mark Pykett, President and CEO of Agilis, presented at the Biotechnology Industry Organization's BIO Investor Forum in San Francisco, CA. Dr. Pykett provided an update on the development progress in the Company's gene therapy programs for Friedreich's Ataxia and Angelman Syndrome, as well as recent findings in disorders involving cognitive impairment. The presentation unveiled new data on the Company's AAV-based delivery of the FXN and UBE3A genes in Friedreich's Ataxia and Angelman Syndrome, respectively, as well as on recent scientific developments using the Company's Reelin technology in Angelman Syndrome and schizophrenia models. Dr. Pykett highlighted Agilis' gene therapy efforts in rare diseases and the potential for innovative gene therapy technologies to provide new treatment paradigms that address the significant unmet need often found in orphan-category diseases, particularly in rare disorders of the central nervous system.

The BIO Investor Forum explores investment trends and opportunities in life sciences, with a focus on venture-stage growth and emerging public companies as well as those poised to join the growth "watch list". The conference features public and venture-stage company presentations, panel discussions and debates, expert-led workshops on the latest market and investment opportunities, and two days of one-on-one investor meetings.

About Agilis Biotherapeutics, LLC

Agilis is advancing innovative DNA therapeutics designed to provide long-term efficacy for patients with debilitating, often fatal, rare genetic diseases that affect the central nervous system. Our therapies are

engineered to impart sustainable clinical benefits, and potentially a functional cure, by inducing persistent expression of a therapeutic gene. The Company's technology is aimed at the precise targeting and restoration of lost gene function, while avoiding unintended off-target effects. Our integrated strategy increases the efficiency of developing DNA therapeutics into safe, targeted gene therapies that achieve long-term efficacy and enable patients to remain asymptomatic without continuous invasive treatment. Agilis' rare disease programs are focused on gene therapy for Friedreich's Ataxia, Angelman Syndrome and Fragile X Syndrome, rare genetic diseases that include severe neurological deficits and result in physically debilitating conditions. Friedreich's Ataxia is the most common hereditary ataxia with an estimated 5,000 to 10,000 patients in the U.S. There are an estimated 10,000 to 15,000 people living with Angelman Syndrome in the US. Fragile X Syndrome is the most common known cause of inherited intellectual disability with an estimated 64,000 patients living in the U.S.

We invite you to visit our website at www.agilisbio.com

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

###

For more information contact:

Agilis Biotherapeutics

Dr. Jodi Cook

Vice President, Operations

Email: jcook@agilisbio.com

Phone: 510-673-7809